[Public Notice+] NK Max to Hold Investor Relations Briefing on the 20th to Strengthen Communication

[Asia Economy Reporter Hyunseok Yoo] NKMAX announced on the 13th that it will hold a corporate presentation focused on individual investors on the 20th. This IR meeting will be held at the Healthcare Innovation Park of Bundang Seoul National University Hospital, where NKMAX's headquarters is located.

Applications to participate in the IR meeting can be made on a first-come, first-served basis for up to 15 people through the banner on the NKMAX website.

An NKMAX IR representative stated, "Starting this year, we planned this IR meeting to actively listen to and communicate with investors in order to maximize shareholder value. There have been few opportunities to introduce the company and its business to individual investors, but through this opportunity, we believe it will be a meaningful occasion to introduce not only institutional investors but also individual investors to the global immune cell therapy market trends and NKMAX's vision for the immune cell therapy business. We plan to hold small-scale IR sessions with the same purpose every month, so we ask for active participation."

Executive Director Ohjin Kwon of NKMAX said, "This year is an important period to review the clinical results being conducted in the United States, Korea, and Mexico," adding, "There is also anticipation for the projects being pursued by the U.S. corporation." He added, "Through active IR activities, we will focus on improving investors' perception of NKMAX and highlighting the growth potential of our core immune cell therapy business sector."

This content was produced with the assistance of AI translation services.